IOVANCE BIOTHERAPEUTICS, INC.
IOVA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for IOVA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · IOVA
Iovance Biotherapeutics is a commercial-stage biotechnology company focused on developing and commercializing tumor-infiltrating lymphocyte (TIL) therapies for cancer, with its first FDA-approved product, Amtagvi, for advanced melanoma.
Key risk: Revenue insufficiency
BioSniper Score
Based on 5 of 6 signals
Market Cap
$3.63B
Cash Runway
16.9 moLead Asset
amtagvi (Approved)
Next Catalyst
Phase2_Start · Sep 1, 2026Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 14 clinical trials · 2 catalysts for IOVANCE BIOTHERAPEUTICS, INC..
Iovance Biotherapeutics is a commercial-stage biotechnology company focused on developing and commercializing tumor-infiltrating lymphocyte (TIL) therapies for cancer, with its first FDA-approved product, Amtagvi, for advanced melanoma.
- Iovance received FDA approval for Amtagvi (lifileucel), a tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma, and is executing its commercial launch [sec_mda · as of 2026-05-07].
- The company reported cash, cash equivalents, short-term investments, and restricted cash of $303.7 million as of August 6, 2026 [sec_mda · as of 2026-08-06].
- Iovance is conducting a registrational study (IOV-LUN-202) in non-small cell lung cancer (NSCLC) and a Phase 3 confirmatory trial (TILVANCE-301) in frontline advanced melanoma [sec_mda · as of 2026-05-07].
- The company has incurred losses and negative cash flows from operations since inception and expects to continue incurring net losses as it invests in commercial and clinical activities [sec_mda · as of 2026-08-06].
- Iovance also markets Proleukin (aldesleukin) in the U.S., with product margins substantially higher than in other markets, to support Amtagvi infusions [sec_mda · as of 2025-05-08].
What works
- Iovance has a commercially approved product, Amtagvi, for advanced melanoma, generating revenue and supporting ongoing clinical programs [sec_mda · as of 2026-05-07].
- The company has a substantial cash position of $303.7 million as of August 6, 2026, providing runway for operations and clinical trials [sec_mda · as of 2026-08-06].
- Iovance is advancing a robust pipeline including a registrational study in NSCLC and a Phase 3 trial in frontline melanoma, targeting large market opportunities [sec_mda · as of 2026-05-07].
What to weigh
- Iovance has incurred losses and negative cash flows from operations since inception and expects to continue incurring net losses [sec_mda · as of 2026-08-06].
- Revenue from Amtagvi and Proleukin may not be material enough to generate positive operational cash flows in the near term [sec_mda · as of 2026-05-07].
- The company faces significant expenses to support the commercial launch of Amtagvi, clinical programs, and pipeline development, with no guarantee of future profitability [sec_mda · as of 2026-05-07].
From the filings
Quoted directly from source documents.
Iovance has a commercial product, Amtagvi, and is executing its launch.
“We expect to continue to incur significant expenses to support our ongoing execution of the commercial launch of Amtagvi”
SEC MD&A · May 7, 2026
Iovance's cash position as of August 6, 2026.
“$303.7 million in cash, cash equivalents, short-term investments, and restricted cash ($110.8 million of cash and cash equivalents, $186.9 million in short-term investments, and $6.0 million in restricted cash)”
SEC MD&A · August 6, 2026
Iovance has incurred losses since inception.
“We have incurred losses and generated negative cash flows from operations since inception.”
SEC MD&A · August 6, 2026
Iovance is conducting a registrational study in NSCLC and a Phase 3 trial in melanoma.
“fund ongoing clinical programs, including our NSCLC registrational study, IOV-LUN-202, and our frontline advanced melanoma Phase 3 confirmatory trial, TILVANCE-301”
SEC MD&A · May 7, 2026
Catalyst timeline
- 2026-09-01 · Phase 2 Start: A Phase 2, Multicenter, Open-label Study of Lifileucel (Tumor-infiltrating Lymphocytes [TIL]) in Par — Initiation of a Phase 2 study for lifileucel in a new indication, which could expand the pipeline.
- 2030-03-01 · Phase 3 Topline: A Phase 3, Multicenter, Randomized, Open-label, Parallel Group, Treatment Study to Assess the Effica — Topline data from a Phase 3 study of pembrolizumab combination, potentially supporting label expansion.
Risks & what to watch (3)›
Key risks
- Revenue insufficiency — Amtagvi and Proleukin revenue may not generate positive operational cash flows in the next 12 months [sec_mda · as of 2026-05-07].
- Continued net losses — Iovance expects to continue incurring net losses as it invests in commercial and clinical activities [sec_mda · as of 2026-08-06].
- Clinical trial risks — Failure of registrational study IOV-LUN-202 or Phase 3 trial TILVANCE-301 could impact pipeline value [sec_mda · as of 2026-05-07].
What to watch
- Commercial adoption and revenue growth of Amtagvi for advanced melanoma [sec_mda · as of 2026-05-07].
- Enrollment and data from the NSCLC registrational study IOV-LUN-202 [sec_mda · as of 2026-05-07].
- Progress of the Phase 3 confirmatory trial TILVANCE-301 in frontline advanced melanoma [sec_mda · as of 2026-05-07].
- Cash burn rate and any future financing needs given ongoing losses [sec_mda · as of 2026-08-06].
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run IOVANCE BIOTHERAPEUTICS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available IOVANCE BIOTHERAPEUTICS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
16.9 months
D/E 0.24
Lead: Approved
5 candidates
2 upcoming, next in ~2d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
287
Total value held
$996.5M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 33,235,474 | $116.7M |
| blackrock, inc. | 31,080,505 | $109.1M |
| mhr fund management llc | 28,967,103 | $101.7M |
| state street corp | 17,448,108 | $61.2M |
| two sigma investments, lp | 13,687,433 | $48.0M |
| vanguard portfolio management llc | 11,700,844 | $41.1M |
| millennium management llc | 9,414,292 | $33.0M |
| goldman sachs group inc | 8,760,060 | $30.7M |
| geode capital management, llc | 8,572,598 | $30.1M |
| invenomic capital management lp | 8,495,551 | $29.8M |
Showing top 10 of 287 institutional holders of IOVANCE BIOTHERAPEUTICS, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 28.4%
- Days to cover
- 7.8
- Shares short
- 108,804,045
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
IOVA short interestGovernance
Frequently asked questions
What is the AI investment thesis for IOVANCE BIOTHERAPEUTICS, INC.?
Iovance Biotherapeutics is a commercial-stage biotechnology company focused on developing and commercializing tumor-infiltrating lymphocyte (TIL) therapies for cancer, with its first FDA-approved product, Amtagvi, for advanced melanoma.
What is IOVANCE BIOTHERAPEUTICS, INC.'s lead drug candidate?
IOVANCE BIOTHERAPEUTICS, INC.'s most advanced tracked candidate is amtagvi (Approved) for Unresectable Melanoma.
What is IOVANCE BIOTHERAPEUTICS, INC.'s next catalyst?
IOVANCE BIOTHERAPEUTICS, INC.'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: A Phase 2, Multicenter, Open-label Study of Lifileucel (Tumor-infiltrating Lymphocytes [TIL]) in Par" — expected September 1, 2026.
Who is the CEO of IOVANCE BIOTHERAPEUTICS, INC.?
Dr. Frederick G. Vogt Esq., J.D., Ph.D. is the chief executive officer of IOVANCE BIOTHERAPEUTICS, INC. (IOVA).
Where is IOVANCE BIOTHERAPEUTICS, INC. headquartered?
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) is headquartered in San Carlos, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.